More Precise RA Patient Care; New data on the 14-3-3? blood test to help optimize treat-to-target strategies

At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Amsterdam on June 13th-16th, leading investigators from United States, Israel, and Egypt will present new data on the 14-3-3η blood test. Several of these studies grow the body of evidence of 14-3-3η’s key role as an early diagnostic test that assists with rheumatoid arthritis (RA) patient management along the disease course. As a highlight, one study describes how 14-3-3η levels can assist with monitoring patients on Tofacitinib therapy. 14-3-3η is a modifiable marker of joint damage progression risk, which makes it ideal to track over time for the optimisation of RA treat-to-target strategies to improve clinical and radiographic outcomes. It is expected that 14-3-3η will have an increasingly important role in the management of RA patients across the entire disease continuum.